ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
23/09/16
Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis—Reply
TM Maher, P Ford, MS Wijsenbeek - JAMA, 2023
… ziritaxestat in patients with IPF are the largest trials ever conducted in IPF and the first phase … Based on experience in other, smaller IPFtrials, 4 ,5 this observation was not unexpected. … forced vital capacity in patients with idiopathic pulmonary …
- ジリタキセスタットと特発性肺線維症における肺機能—返信
Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis
L Kawano-Dourado, M Funke-Chambour, AU Wells - JAMA, 2023
To the Editor We are writing about the ISABELA 1 and 2 randomized clinical trials1 that tested 2 doses of ziritaxestat (600 mg or 200 mg) vs placebo in patients with idiopathic pulmonaryfibrosis (IPF) who were also receiving treatment with standard …
- ジリタキセスタットと特発性肺線維症における肺機能
[PDF] Regulatory effect and mechanism of LncRNA SOX2OT in idiopathic pulmonary fibrosis
M Qiao, D Li, Y He, Q Cui, X Li, H Chi - Cellular and Molecular Biology, 2023
… on IPF under hypoxia conditions, this study aims to provide new references and guidance for the future diagnosis and treatment of IPF. … This study discusses the role played by long noncoding RNA (lncRNA) SOX2OT (SOX2OT) in idiopathic …
- 特発性肺線維症におけるLncRNA SOX2OTの制御効果と機構
[PDF] Autoantibody Positivity in Idiopathic Pulmonary Fibrosis: Outcomes From the Pulmonary Fibrosis Foundation Patient Registry
C Newton, T Kulkarni, MB Scholand, K Flaherty, Z Li…
… Patients with IPF enrolled in the PFF-PR who had serology records and an IPF diagnosis within 1 year of consent were included in this … clinical outcomes in patients with IPF. However, there was a non-significant trend towards a difference in …
- 特発性肺線維症における自己抗体陽性: 肺線維症財団患者登録からの結果
[PDF] Initial Results with [18F] FAPI-74 PET/CT in Idiopathic Pulmonary Fibrosis
Y Mori, V Kramer, E Novruzov, E Mamlins, M Röhrich… - 2023
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68 Ga-labelled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18 …
- 特発性肺線維症における[18F] FAPI-74 PET/CTの初期結果
[PDF] Holistic management of patients with progressive pulmonary fibrosis
A Oliveira, G Fabbri, T Gille, E Bargagli, B Duchemann… - Breathe, 2023
… Several interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are characterised by progressive fibrosis (figure 1), and share similar disease behaviour, impacts and needs. These diseases lead to limitations in daily activities …
- 進行性肺線維症患者の総合的管理
Optimal controlling of anti-TGF-[Formula: see text] and anti-PDGF medicines for preventing pulmonary fibrosis.
A Malek - Scientific Reports, 2023
… The novel optimal regulator control problem with two controls (medicines) is proposed to simulate how to the preventing pulmonaryfibrosis. Idiopathic pulmonary fibrosis (IPF) consists of restoring a system of cells, protein, and tissue networks with …
- 肺線維症を予防するための抗TGF-[式：本文参照]および抗PDGF薬の最適な制御。
[HTML] Optimal controlling of anti-TGF-β and anti-PDGF medicines for preventing pulmonary fibrosis
F Bahram Yazdroudi, A Malek - Scientific Reports, 2023
… The novel optimal regulator control problem with two controls (medicines) is proposed to simulate how to the preventing pulmonaryfibrosis. Idiopathic pulmonary fibrosis (IPF) consists of restoring a system of cells, protein, and tissue networks with …
- 肺線維症予防のための抗TGF-β薬および抗PDGF薬の最適制御
[PDF] Tacrolimus and the Treatment of Pulmonary Fibrosis
D Huang, Y Li, Y Liu - American journal of respiratory and critical care …, 2023
… Idiopathic pulmonary fibrosis (IPF) is characterized by irreversible lung scarring; however, the … to elucidate a mechanistic connection between IPF and pulmonary hypertension (PH).(1) … mouse model of TGF-β1-induced pulmonary fibrosis …
- タクロリムスと肺線維症の治療
Epithelial-fibroblast interactions in IPF: Lessons from in vitro co-culture studies
J Brussow, K Feng, F Thiam, S Phogat, ET Osei - Differentiation, 2023
… Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial disease that is characterized … The activated and differentiated (myo)fibroblasts are one of the main sources of tissue remodeling in IPF … in various lung diseases including IPF …
- IPFにおける上皮-線維芽細胞の相互作用: in vitro共培養研究からの教訓
23/09/14
Monocytes and Macrophages: Emerging Mechanisms and Novel Therapeutic Targets in Pulmonary Fibrosis
CY Perrot, T Karampitsakos, JD Herazo-Maya - American Journal of Physiology-Cell …, 2023
… prognoses of patients with idiopathicpulmonary fibrosis. PLoS One. 529 2010;5(1):e8959. … +CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. American journal of 534 … marker 743 for idiopathic pulmonary fibrosis: analysis from the …
- 単球とマクロファージ：肺線維症における新たなメカニズムと新規治療標的
[PDF] Photodermatit developed with pirfenidone treatment in patient diagnosed with IPF
E Akkuş, D Çelik, Ö Yetkin, H Lakadamyalı - Journal of Pulmonology and Intensive …, 2023
… Idiopathic pulmonary fibrosis (IPF) is the most common of the major idiopathic interstitial pneumonia (IIP) of unknown etiology, often presenting in advanced age, limited to the lungs, characterized by histopathologically and/or radiologically usual …
- IPFと診断された患者のピルフェニドン治療により光皮膚炎が発症
Comorbidity of Pulmonary Fibrosis and COPD/Emphysema: Research Status, Trends, and Future Directions---------A Bibliometric Analysis from 2004 to 2023
H Fang, T Dong, Z Han, S Li, M Liu, Y Liu, Q Yang… - International Journal of …, 2023
… , associated autoimmune disorders, idiopathic pulmonary fibrosis, interstitial lung disease … and transforming growth factors in idiopathic pulmonary fibrosis. David Hansell from Imperial … with pulmonary fibrosis, including idiopathic interstitial …
The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
A Vats, P Chaturvedi - Stem Cells and Cloning: Advances and Applications, 2023
… of idiopathic pulmonary fibrosis (IPF) and COVID-19-related pulmonary fibrosis could providing valuable insights into novel treatment approaches for both conditions, allowing for early intervention and better management of lung complications …
- 幹細胞の再生力: ブレオマイシン誘発性肺線維症の治療
Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease
X Ren, T Yang, K Zhang, Y Liu, C Wang, L Wu, J Zhang - International Journal of …, 2023
… Other than pirfenidone and nintedanib for the therapy of idiopathic pulmonary fibrosis, no medications are currently licensed for the treatment of ILD. Luteolin is a common flavonoid with multiple biological effects such as anti-inflammation but with …
- シクロデキストリン MOF で修飾された乾燥粉末吸入器は、線維化性間質性肺疾患を改善するためにルテオリンの生物学的利用能を 4 倍に高める
23/09/12
Identification and immunological characterization of PLA2G2A and cell death-associated molecular clusters in idiopathic pulmonary fibrosis
W Lv, H Mao, Y Ruan, S Li, K Shimizu, L Zhang… - Life Sciences, 2023
… Idiopathic pulmonary fibrosis (IPF) is a severe pulmonary interstitial pneumonia. Our study focuses on the role of PLA2 enzyme in the IPF to explore a more effective diagnosis and treatment mechanism of IPF. … Idiopathicpulmonary fibrosis (IPF) is …
- 特発性肺線維症における PLA2G2A および細胞死関連分子クラスターの同定と免疫学的特性評価
Integrative analysis reveals the recurrent genetic etiologies in idiopathic pulmonary fibrosis
S Guo, Y Dong, C Wang, Y Jiang, R Xiang, LL Fan… - QJM: An International …, 2023
Background Idiopathic pulmonary fibrosis(IPF) is increasingly recognized as a chronic, progressive, and fatal lung disease with an unknown etiology. Current studies focus on revealing the genetic factors in the risk of IPF, making the …
- 統合解析により特発性肺線維症の再発性遺伝病因が明らかに
[HTML] Asarinin attenuates bleomycin-induced pulmonary fibrosis by activating PPARγ
Q Zeng, T Zhou, W Huang, X Huang, L Huang, X Zhang… - Scientific Reports, 2023
… Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease that lacks effective treatment modalities. Once patients … observed the anti-pulmonaryfibrosis effect of asarinin in a BLM-induced mouse model of pulmonary fibrosis and …
- アサリニンは PPARγ を活性化することでブレオマイシン誘発性肺線維症を軽減
MICALL2 participates in the regulation of epithelial-mesenchymal transition in alveolar epithelial cells–Potential role in pulmonary fibrosis
Y Chen, W Song, H Zhang, X Ji - Archives of Biochemistry and Biophysics, 2023
… Epithelial-mesenchymal transition (EMT) of alveolar epithelial cells is a vital process in idiopathic pulmonary fibrosis (IPF), which results in … in the lungs of IPF mice and alveolar epithelial type II (ATII) cells from IPF patients, and aimed to …
- MICALL2 は肺胞上皮細胞の上皮間葉転換の調節に関与する – 肺線維症における潜在的な役割
Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease
F Saleem, CJ Ryerson, N Sarma, K Johannson… - Annals of the American …, 2023
… Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: … Exertional desaturation in idiopathic pulmonaryfibrosis: The role of oxygen supplementation in … Ascertainment of individual risk of mortality for …
- 線維性間質性肺疾患における新たに発症する労作時および安静時低酸素血症の予測
Neutrophil extracellular traps are involved in the occurrence of interstitial lung disease in a murine experimental autoimmune myositis model
L Bai, J Zhu, W Ma, F Li, P Zhao, S Zhang - Clinical and Experimental Immunology, 2023
… Abstract:The excessive formation of neutrophil extracellular traps (NETs) has been demonstrated to be a pathogenic mechanism of idiopathic … At present, bleomycininduced pulmonary fibrosis mouse model is the most commonly used …
- 好中球細胞外トラップはマウス実験的自己免疫性筋炎モデルにおける間質性肺疾患の発生に関与する
[PDF] Bronchial epithelial and airway smooth muscle cell interactions in health and disease
R Abohalaka - Heliyon, 2023
… Chronic pulmonary diseases such as asthma, COPD, and Idiopathic pulmonary fibrosis are … pulmonary diseases, such as IdiopathicPulmonary Fibrosis (IPF), place a significant burden on … unsurprising that chronic lung diseases such as …
- 健康と病気における気管支上皮と気道平滑筋細胞の相互作用
[PDF] Differential effects of prolyl-3-hydroxylases 1 and 4 on collagen biosynthesis highlight prolyl-3-hydroxylase 4 as a potential novel drug target in pulmonary fibrosis
C Onursal - 2023
… Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and incurable interstitial lung disease (ILD) with an average life expectancy of … Many questions about the etiology of IPF remain unanswered. IPF is characterized by an abnormal deposition …
- コラーゲン生合成に対するプロリル-3-ヒドロキシラーゼ 1 と 4 の異なる効果により、プロリル-3-ヒドロキシラーゼ 4 が肺線維症における新規薬剤標的となる可能性があることが明らかに
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
